Trial reportStem cells and development2012
Oral mucosal progenitor cells are potently immunosuppressive in a dose-independent manner.
Trial report in Stem cells and development, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Stem cell-derived exosomes in wound healing: mechanistic insights and delivery strategies.Regenerative medicine · 2025Review
- Antibiotic carry over is a confounding factor for cell-based antimicrobial research applications.Scientific reports · 2025Article
- Stem cells and extracellular vesicles to improve preclinical orofacial soft tissue healing.Stem cell research & therapy · 2023Review
- Understanding Scarring in the Oral Mucosa.Advances in wound care · 2022Review
- Immune Tolerance in the Oral Mucosa.International journal of molecular sciences · 2021Review
- Stromal Heterogeneity in the Human Proliferative Endometrium-A Single-Cell RNA Sequencing Study.Journal of personalized medicine · 2021Article
- Stemness Potency of Human Gingival Cells-Application in Anticancer Therapies and Clinical Trials.Cells · 2020Review
- Endometrial stromal cells exhibit a distinct phenotypic and immunomodulatory profile.Stem cell research & therapy · 2020Article
- Immunomodulatory effects of interferon-γ on human fetal cardiac mesenchymal stromal cells.Stem cell research & therapy · 2019Article
- Review
- Immunological Properties of Neural Crest Cells Derived from Human Induced Pluripotent Stem Cells.Stem cells and development · 2019Article
- Stem Cells in Dentistry: Types of Intra- and Extraoral Tissue-Derived Stem Cells and Clinical Applications.Stem cells international · 2018Review
- Adult Stem Cells of Orofacial Origin: Current Knowledge and Limitation and Future Trend in Regenerative Medicine.Tissue engineering and regenerative medicine · 2017Review
- Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro.Stem cells translational medicine · 2016Article
- Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy.Scientific reports · 2016Article
- Oral Mucosal Lamina Propria-Progenitor Cells Exert Antibacterial Properties via the Secretion of Osteoprotegerin and Haptoglobin.Stem cells translational medicine · 2015Article
- Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?Stem cells (Dayton, Ohio) · 2014Article
- Prospects for therapeutic tolerance in humans.Current opinion in rheumatology · 2014Review
- Inhibition of the differentiation of monocyte-derived dendritic cells by human gingival fibroblasts.PloS one · 2013Article
- Human oral mucosa and gingiva: a unique reservoir for mesenchymal stem cells.Journal of dental research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Oral mucosal lamina propria progenitor cells (OMLP-PCs) are a novel, clonally derived PC population of neural crest origin with the potential to differentiate down both mesenchymal and neuronal cell lineages. In this study we aimed to determine the immunological properties of OMLP-PCs and to establish whether they would be suitable candidates for allogeneic tissue engineering and in the treatment of immune-related diseases. OMLP-PCs demonstrated no inherent immunogenicity with insignificant expression of costimulatory molecules (CD40, CD80, CD86, CD154, and CD178) or human leukocyte antigen (HLA) class II. OMLP-PCs required 7 days of stimulation with interferon-γ (IFN-γ) to induce cell surface expression of HLA II. Mixed lymphocyte cultures and mitogen stimulation demonstrated the potent immunosuppressive capability of OMLP-PCs in a contact-independent manner. Complete inhibition of lymphocyte proliferation was seen at doses as low as 0.001% OMLP-PCs to responder lymphocytes, while annexin V staining confirmed that this immunosuppressive effect was not due to the induction of lymphocyte apoptosis. These data demonstrate, for the first time, that OMLP-PC immunomodulation, unlike that for mesenchymal stem cells, occurs via a dose- and HLA II-independent mechanism by the release of immunosuppressive soluble factors and suggests these cells may have wide ranging potential in future immune-related therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.